Cargando…
Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada
Background. Since 2002, the Model of End-Stage Liver Disease (MELD) has been used for allocation of liver transplants (LT) in the USA. In Canada, livers were allocated by the CanWAIT algorithm. The aim of this study was to compare the abilities of MELD, Child-Pugh (CP), and CanWAIT status to predict...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904690/ https://www.ncbi.nlm.nih.gov/pubmed/27446823 http://dx.doi.org/10.1155/2016/1329532 |
_version_ | 1782437188167794688 |
---|---|
author | Burak, Kelly W. Meeberg, Glenda A. Myers, Robert P. Fick, Gordon H. Swain, Mark G. Bain, Vincent G. Kneteman, Norman M. Hilsden, Robert J. |
author_facet | Burak, Kelly W. Meeberg, Glenda A. Myers, Robert P. Fick, Gordon H. Swain, Mark G. Bain, Vincent G. Kneteman, Norman M. Hilsden, Robert J. |
author_sort | Burak, Kelly W. |
collection | PubMed |
description | Background. Since 2002, the Model of End-Stage Liver Disease (MELD) has been used for allocation of liver transplants (LT) in the USA. In Canada, livers were allocated by the CanWAIT algorithm. The aim of this study was to compare the abilities of MELD, Child-Pugh (CP), and CanWAIT status to predict 3-month and 1-year mortality before LT in Canadian patients and to describe the use of MELD in Canada. Methods. Validation of MELD was performed in 320 patients listed for LT in Alberta (1998–2002). In October 2014, a survey of MELD use by Canadian LT centers was conducted. Results. Within 1 year of listing, 47 patients were removed from the waiting list (29 deaths, 18 too ill for LT). Using logistic regression, the MELD and CP were better than the CanWAIT at predicting 3-month (AUROC: 0.79, 0.78, and 0.59; p = 0.0002) and 1-year waitlist mortality (AUROC: 0.70, 0.70, and 0.55; p = 0.0023). Beginning in 2004, MELD began to be adopted by Canadian LT programs but its use was not standardized. Conclusions. Compared with the CanWAIT system, the MELD score was significantly better at predicting LT waitlist mortality. MELD-sodium (MELD-Na) has now been adopted for LT allocation in Canada. |
format | Online Article Text |
id | pubmed-4904690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-49046902016-06-30 Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada Burak, Kelly W. Meeberg, Glenda A. Myers, Robert P. Fick, Gordon H. Swain, Mark G. Bain, Vincent G. Kneteman, Norman M. Hilsden, Robert J. Can J Gastroenterol Hepatol Research Article Background. Since 2002, the Model of End-Stage Liver Disease (MELD) has been used for allocation of liver transplants (LT) in the USA. In Canada, livers were allocated by the CanWAIT algorithm. The aim of this study was to compare the abilities of MELD, Child-Pugh (CP), and CanWAIT status to predict 3-month and 1-year mortality before LT in Canadian patients and to describe the use of MELD in Canada. Methods. Validation of MELD was performed in 320 patients listed for LT in Alberta (1998–2002). In October 2014, a survey of MELD use by Canadian LT centers was conducted. Results. Within 1 year of listing, 47 patients were removed from the waiting list (29 deaths, 18 too ill for LT). Using logistic regression, the MELD and CP were better than the CanWAIT at predicting 3-month (AUROC: 0.79, 0.78, and 0.59; p = 0.0002) and 1-year waitlist mortality (AUROC: 0.70, 0.70, and 0.55; p = 0.0023). Beginning in 2004, MELD began to be adopted by Canadian LT programs but its use was not standardized. Conclusions. Compared with the CanWAIT system, the MELD score was significantly better at predicting LT waitlist mortality. MELD-sodium (MELD-Na) has now been adopted for LT allocation in Canada. Hindawi Publishing Corporation 2016 2016-04-03 /pmc/articles/PMC4904690/ /pubmed/27446823 http://dx.doi.org/10.1155/2016/1329532 Text en Copyright © 2016 Kelly W. Burak et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Burak, Kelly W. Meeberg, Glenda A. Myers, Robert P. Fick, Gordon H. Swain, Mark G. Bain, Vincent G. Kneteman, Norman M. Hilsden, Robert J. Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada |
title | Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada |
title_full | Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada |
title_fullStr | Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada |
title_full_unstemmed | Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada |
title_short | Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada |
title_sort | validation of the model of end-stage liver disease for liver transplant allocation in alberta: implications for future directions in canada |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904690/ https://www.ncbi.nlm.nih.gov/pubmed/27446823 http://dx.doi.org/10.1155/2016/1329532 |
work_keys_str_mv | AT burakkellyw validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada AT meebergglendaa validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada AT myersrobertp validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada AT fickgordonh validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada AT swainmarkg validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada AT bainvincentg validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada AT knetemannormanm validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada AT hilsdenrobertj validationofthemodelofendstageliverdiseaseforlivertransplantallocationinalbertaimplicationsforfuturedirectionsincanada |